Superworth

Astrana Health price to sales ratio ASTH

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026
0.5×
10-year median
1.4×
Against its 10-year history
7th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.4× to 8.9×
Peer median
1.2×

Astrana Health's price to sales ratio is 0.5× as of Oct 23, 2026.

That is below its ten-year median of 1.4×, lower than on 93% of days in the last ten years.

Over that time it ranged from 0.4× in Feb 2026 to 8.9× in Jul 2021.

The median for 9 consulting Services stocks of a similar size is 1.2×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.5×0.4×0.8×
20250.5×0.4×1.3×
20241.1×1.1×2.1×
20231.7×1.3×2.0×
20221.6×1.5×4.4×
20215.4×1.7×8.9×
20201.4×0.9×1.8×
20191.3×1.0×1.5×
20181.4×0.8×1.6×
20171.3×0.4×1.3×
20160.9×0.4×1.0×
20150.6×0.6×1.7×
20141.0×0.7×3.3×
20132.4×1.5×4.1×
20125.1×0.5×6.2×

Against its peers

Companies in Consulting Services nearest Astrana Health's size, closest first, today.

CompanyPrice to sales ratio
ASTHAstrana Health0.5×
ICFIICF International0.9×
HURNHuron Consulting1.7×
EXPOExponent5.8×
FCNFTI Consulting1.1×
BWMNBowman Consulting1.4×
GGenpact LTD1.3×
BAHBooz Allen Hamilton0.8×
HCKTHackett1.1×
IIIInformation Services1.2×
Peer median1.2×

Where Astrana Health ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Astrana Health

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.